Optimal Duration of Consolidation Durvalumab Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: A Multi-institutional Retrospective Study

期刊论文
发表日期：

2024年11月7日

查看全文

Hiroshi Doi,
Yukinori Matsuo,
Noriko Kishi,
Masakazu Ogura,
Takamasa Mitsuyoshi,
Nami Ueki,
Kazuhito Ueki,
Kota Fujii,
Masato Sakamoto,
Tomoko Atsuta,
Tomohiro Katagiri,
Takashi Sakamoto,
Masaru Narabayashi,
Shuji Ohtsu,
Satsuki Fujishiro,
Takahiro Kishi,
Takashi Mizowaki

摘要

Background

Although durvalumab has shown promise in improving survival rates in patients with locally advanced non-small cell lung cancer (NSCLC), the ideal duration of treatment has yet to be established.

Objective

The primary objective of this study was to determine the optimal number of durvalumab cycles following definitive chemoradiotherapy for locally advanced NSCLC.

Patients and Methods

A total of 178 patients who received chemoradiotherapy for stage III NSCLC at 15 institutions were retrospectively analyzed. Progression-free survival (PFS) and overall survival (OS) were assessed according to the number of consolidation durvalumab cycles by landmark analysis. Landmark analyses were performed at 3-month intervals from the start of durvalumab treatment to 9 months.

Results

The median number of durvalumab cycles was 16 (range 1–27). PFS and OS were significantly better in patients who received ≥20 cycles of durvalumab than in those who did not (p < 0.001 and p < 0.001, respectively). In landmark analysis, significant differences were observed in PFS from 0 to 6 months and OS from 3 to 6 months between patients who continued durvalumab after the time point and those who did not. However, there were no significant differences in PFS or OS between patients who received 13–19 or ≥20 cycles of durvalumab at 9 months.

Conclusions

Durvalumab should be administered for more than 6 months to contribute to the main benefits of consolidation therapy following chemoradiotherapy.